PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.
Lymphoma
DRUG: PEG-rhG-CSF
The occurrence rate of adverse event, up to 30 days after the patient study completion|The severity of adverse event, up to 30 days after the patient study completion
the occurrence rate of grade III/ IV neutropenia during chemotherapy cycles, through the study completion,an average of 5 months
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.